Literature DB >> 18184926

COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity.

Gustavo Fenalti1, Christiane S Hampe, Yasir Arafat, Ruby H P Law, J Paul Banga, Ian R Mackay, James C Whisstock, Ashley M Buckle, Merrill J Rowley.   

Abstract

OBJECTIVE: To gain structural insights into the autoantigenic properties of GAD65 in type 1 diabetes, we analyzed experimental epitope mapping data in the context of the recently determined crystal structures of GAD65 and GAD67, to allow "molecular positioning" of epitope sites for B- and T-cell reactivity. RESEARCH DESIGN AND METHODS: Data were assembled from analysis of reported effects of mutagenesis of GAD65 on its reactivity with a panel of 11 human monoclonal antibodies (mAbs), supplemented by use of recombinant Fab to cross-inhibit reactivity with GAD65 by radioimmunoprecipitation of the same mAbs.
RESULTS: The COOH-terminal region on GAD65 was the major autoantigenic site. B-cell epitopes were distributed within two separate clusters around different faces of the COOH-terminal domain. Inclusion of epitope sites in the pyridoxal phosphate-and NH(2)-terminal domains was attributed to the juxtaposition of all three domains in the crystal structure. Epitope preferences of different mAbs to GAD65 aligned with different clinical expressions of type 1 diabetes. Epitopes for four of five known reactive T-cell sequences restricted by HLA DRB1*0401 were aligned to solvent-exposed regions of the GAD65 structure and colocalized within the two B-cell epitope clusters. The continuous COOH-terminal epitope region of GAD65 was structurally highly flexible and therefore differed markedly from the equivalent region of GAD67.
CONCLUSIONS: Structural features could explain the differing antigenicity, and perhaps immunogenicity, of GAD65 versus GAD67. The proximity of B- and T-cell epitopes within the GAD65 structure suggests that antigen-antibody complexes may influence antigen processing by accessory cells and thereby T-cell reactivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184926     DOI: 10.2337/db07-1461

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  20 in total

1.  Novel autoantigens in type 1 diabetes.

Authors:  Shuhong Han; William Donelan; Hai Wang; Westley Reeves; Li-Jun Yang
Journal:  Am J Transl Res       Date:  2013-05-24       Impact factor: 4.060

2.  Reduced display of conformational epitopes in the N-terminal truncated GAD65 isoform: relevance for people with stiff person syndrome or DQ8/8-positive Type 1 diabetes mellitus.

Authors:  C S Hampe; J R Radtke; A Wester; A Carlsson; E Cedervall; B Jönsson; S A Ivarsson; H Elding Larsson; K Larsson; B Lindberg; J Neiderud; O Rolandsson; Å Lernmark
Journal:  Diabet Med       Date:  2018-12-28       Impact factor: 4.359

3.  GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.

Authors:  Camilla Skoglund; Mikael Chéramy; Rosaura Casas; Johnny Ludvigsson; Christiane S Hampe
Journal:  Pediatr Diabetes       Date:  2011-08-16       Impact factor: 4.866

Review 4.  Islet autoantigens: structure, function, localization, and regulation.

Authors:  Peter Arvan; Massimo Pietropaolo; David Ostrov; Christopher J Rhodes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

5.  Comparison of three assays for the detection of GAD65Ab-specific anti-idiotypic antibodies.

Authors:  Shilpa Oak; Jared Radtke; Mona Landin-Olsson; Carina Törn; Ake Lernmark; Christiane S Hampe
Journal:  J Immunol Methods       Date:  2009-09-23       Impact factor: 2.303

6.  The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes.

Authors:  Shilpa Oak; Lisa K Gilliam; Mona Landin-Olsson; Carina Törn; Ingrid Kockum; Christina R Pennington; Merrill J Rowley; Michael R Christie; J Paul Banga; Christiane S Hampe
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-26       Impact factor: 11.205

7.  GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA).

Authors:  Roberto Towns; Massimo Pietropaolo
Journal:  Drugs Future       Date:  2011-11       Impact factor: 0.148

8.  An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.

Authors:  Bindu Jayakrishnan; David E Hoke; Christopher G Langendorf; Ashley M Buckle; Merrill J Rowley
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

9.  Detection of autoantibodies against reactive oxygen species modified glutamic acid decarboxylase-65 in type 1 diabetes associated complications.

Authors:  Mohd Wajid Ali Khan; Kamalpreet Banga; Subhash N Mashal; Wahid Ali Khan
Journal:  BMC Immunol       Date:  2011-03-08       Impact factor: 3.615

10.  Characterisation of peptide microarrays for studying antibody-antigen binding using surface plasmon resonance imagery.

Authors:  Claude Nogues; Hervé Leh; Christopher G Langendorf; Ruby H P Law; Ashley M Buckle; Malcolm Buckle
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.